HCW Biologics/HCWB

$1.70

11.11%
-
1D1W1MYTD1YMAX

About HCW Biologics

HCW Biologics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, and autoimmune diseases. The Company uses its Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is designed to treat the impact of accumulated senescent cells and the senescence-associated phenotype (SASP) factors which they secrete by eliminating senescent cells and reducing SASP factors. HCW9218 is being evaluated in two clinical trials. HCW9302 is designed to activate and expand regulatory T (Treg) cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors.

Ticker

HCWB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Hing Wong

Employees

44

Headquarters

Miramar, United States

HCW Biologics Metrics

BasicAdvanced
$55.04M
Market cap
-
P/E ratio
-$0.55
EPS
-
Beta
-
Dividend rate

What the Analysts think about HCW Biologics

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
252.94% upside
High $8.00
Low $4.00
$1.70
Current price
$6.00
Average price target

HCW Biologics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-612.5% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$800K
33.33%
Net income
$-4.9M
13.95%
Profit margin
-612.5%
-14.53%

HCW Biologics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.69%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.15
-$0.14
-$0.12
-$0.14
-
Expected
-$0.17
-$0.14
-$0.15
-$0.13
-$0.14
Surprise
-9.09%
0%
-18.18%
7.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell HCW Biologics stock

Buy or sell HCW Biologics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing